Pneumagen Announces First Patient Dosed in Phase 2 Proof of Concept Influenza Challenge Study Assessing Neumifil, an Intranasal Broad-Spectrum Antiviral

ST ANDREWS, Scotland, Aug. 16, 2022. Pneumagen, a clinical stage biotech company developing Neumifil, an intranasal, broad-spectrum antiviral treatment to prevent or, if infected reduce and manage viral respiratory tract infections, today announced...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials